Millennium Pharmaceutical Becomes First Licensed Customer for BioClinica's New Enterprise Demand Aggregator

-- Will Provide Enterprise-Wide Control for Clinical Supply Planning and Manufacturing --

NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, has signed a technology agreement with Millennium: The Takeda Oncology Company, (Millennium) a leading biopharmaceutical company. This agreement makes Millennium the first customer for BioClinica's new Enterprise Demand Aggregator ("EDA") product offering. As part of the agreement BioClinica and Millennium will work in partnership to speed the release of the product which will advance Millennium's clinical trial supply planning across all their global clinical trials.

Millennium has been using BioClinica Optimizer since 2007 to improve their ability to forecast clinical trial supplies and simulate their studies' requirements, resulting in greater efficiencies and cost benefits. "As we now want to improve and standardize our clinical supply forecasting and management across multiple trials with greater control than ever before, BioClinica's Enterprise Demand Aggregator application is a great addition for us," said Paul Skerker, Ph.D., Senior Director of Investigational Supply Operations for Millennium.

BioClinica's EDA will collect planning information from all of Millennium's Optimizer-simulated protocols in a central repository and provide an enterprise-wide view of the demand over time.

"BioClinica is introducing another eClinical offering which we anticipate will become an industry standard. We believe our rapidly expanding clinical and supply chain solutions are individually best-in-class, and the integration of our product offerings drive benefits unmatched in the industry," said Peter Benton, President of eClinical Solutions for BioClinica. "The pharmaceutical industry relies on technology innovation to drive necessary efficiencies. This partnership demonstrates Millennium's commitment to innovate while also validating the benefits that BioClinica's Optimizer technology provides."

Enterprise Demand Aggregator features will extend the capabilities of BioClinica Optimizer, including:

  • Macro level forecasts for studies in the early planning stages
  • Clinical supplies forecasts per study or program
  • Analysis of full enterprise demand against capacity
  • The ability to run "what if's" scenarios over time, and
  • Integration with other supply chain systems (MRP, ERP)

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.

About BioClinica

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.